Dendreon Considering Neuvenge as Tradename for Cancer Vaccine APC-8024
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Dendreon may use the name Neuvenge for its cancer vaccine APC-8024, the firm said. The company submitted the tradename to the Patent and Trademark Office for pharmaceuticals used in cancer treatment. The company is also considering other names for APC-8024.